Breaking News Instant updates and real-time market news.

JBLU

JetBlue

$19.33

-0.03 (-0.15%)

05:06
04/12/18
04/12
05:06
04/12/18
05:06

JetBlue valuation attractive at current share levels, says Imperial Capital

Imperial Capital analyst Michael Derchin calls JetBlue Airways' valuation attractive at current share levels following the company's March traffic report. The company indicated Q1 unit revenues are expected to increase 6.1% versus initial guidance of 2.5%-5.5%, Derchin tells investors in a research note. He believes JetBlue s likely to have strong earnings growth through fiscal 2019 despite a potential pilot's contract. The analyst keeps an Outperform rating on the shares with a $31 price target.

  • 24

    Apr

JBLU JetBlue
$19.33

-0.03 (-0.15%)

01/30/18
JPMS
01/30/18
DOWNGRADE
Target $67
JPMS
Underweight
Alaska Air downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jamie Baker downgraded Alaska Air Group (ALK) to Underweight and lowered his price target for the shares to $67 from $74. The analyst notes that Alaska Air is the only name where he had to cut his 2019 estimates. He also believes the company "remains in the United crosshairs in San Francisco." Alaska is also slightly more expensive than JetBlue on 2019 earnings, Baker tells investors in a research note. The analyst this morning also Southwest (LUV) to Neutral and upgraded both JetBlue (JBLU) and United Continental (UAL) to Overweight.
01/30/18
01/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Strong Buy from Buy at Needham by analyst Kevin Caliendo, who contended that the stock remains underowned and, unlike its peers, yet to rally beyond the expectations of benefits from the tax changes. The analyst says the company's multiple has remained constant despite the expansion in the rest of the pharma services industry, forecasting EPS growth of 8%-10% beyond the modeled $8 per share in 2019. 2. JetBlue (JBLU) upgraded to Overweight from Neutral at JPMorgan by analyst Jamie Bakier who said the company's costs are "gradually coming under control" and its balance sheet is "sound." The analyst also upgraded United Continental (UAL) to Overweight from Underweight, saying the shares are the "cheapest in the sector and among the most washed out, having declined the most from recent highs." 3. Gilead (GILD) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who said that tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018. 4. Intel (INTC) upgraded to Buy from Neutral at Citi by analyst Christopher Danely, who said overly conservative guidance and poor sentiment from years of underperformance should drive estimates and the stock higher in the near term. He believes management's "new habit" of conservative guidance is good for the stock. 5. Albemarle (ALB) upgraded to Buy from Neutral at UBS by analyst John Roberts, who said the stock is down 23% from the November high despite no change to the outlook for lithium. The analyst attributes the pullback to larger scale lithium expansion announcements and raising concerns of potential oversupply. He believes the market is pricing in 10% annual realized price declines for Albemarle over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
WOLF
02/12/18
UPGRADE
WOLF
Peer Perform
JetBlue upgraded to Peer Perform from Underperform at Wolfe Research
03/09/18
JPMS
03/09/18
NO CHANGE
JPMS
JPMorgan sees Airlines raising Q1 outlooks at next week's conference
JPMorgan analyst James Baker believes several Airlines will raise their Q1 guidance at his firm's Aviation, Transportation and Industrials Conference next week. He expects near-term consensus estimates to move higher for the airlines coming out of the presentations, particularly for United Continental (UAL). The analyst recommends increasing exposure to the sector ahead of the conference. He raised his estimates for United the most, taking his Q1 earnings per share forecast up to 32c from 3c. Other names in the space include American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU) and Southwest (LUV).

TODAY'S FREE FLY STORIES

AMRN

Amarin

$2.94

-0.05 (-1.67%)

05:34
04/23/18
04/23
05:34
04/23/18
05:34
Hot Stocks
Amarin promotes Aaron Berg to Chief Commercial Officer »

Amarin announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARES

Ares Management

05:32
04/23/18
04/23
05:32
04/23/18
05:32
Hot Stocks
Ares Management acquires Pan-European office portfolio »

Ares Management announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

RHHBY

Roche

05:30
04/23/18
04/23
05:30
04/23/18
05:30
Hot Stocks
Genentech says 4 years of continuous Ocrevus treatment reduces RMS activity »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 21

    May

  • 30

    May

UBS

UBS

$17.66

-0.005 (-0.03%)

05:27
04/23/18
04/23
05:27
04/23/18
05:27
Earnings
UBS reports Q1 EPS CHF 0.39 vs. CHF 0.33 last year »

Reports Q1 profit before…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    May

BHVN

Biohaven Pharmaceutical

$27.19

-0.07 (-0.26%)

05:21
04/23/18
04/23
05:21
04/23/18
05:21
Hot Stocks
Biohaven announces key secondary outcome measures from rimegepant Phase 3 trials »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 12

    Jun

OPBK

OP Bancorp

05:12
04/23/18
04/23
05:12
04/23/18
05:12
Initiation
OP Bancorp initiated  »

OP Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$58.82

0.18 (0.31%)

05:11
04/23/18
04/23
05:11
04/23/18
05:11
Upgrade
Merck rating change  »

Merck upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 27

    Apr

  • 01

    May

  • 08

    May

  • 05

    Jun

  • 23

    Oct

BDORY

Banco do Brasil

05:04
04/23/18
04/23
05:04
04/23/18
05:04
Downgrade
Banco do Brasil rating change  »

Banco do Brasil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$99.64

-4.57 (-4.39%)

05:02
04/23/18
04/23
05:02
04/23/18
05:02
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

KORS

Michael Kors

$65.02

-0.7 (-1.07%)

04:57
04/23/18
04/23
04:57
04/23/18
04:57
Upgrade
Michael Kors rating change  »

Deutsche Bank upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.60

-0.47 (-3.60%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Syros Pharmaceuticals management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    May

AVEO

Aveo Oncology

$2.59

-0.05 (-1.89%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aveo Oncology management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

KMB

Kimberly-Clark

$100.04

-3.3 (-3.19%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

INFY

Infosys

$17.38

0.21 (1.22%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Infosys to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

CIGI

Colliers International

$70.20

0.75 (1.08%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
UBS REITs analyst to hold an analyst/industry conference call »

REITs Analyst Yulico,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 30

    Apr

  • 01

    May

CNAT

Conatus

$3.58

0.02 (0.56%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Conatus management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Existing Home Sales to be reported at 10:00 »

March Existing Home Sales…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MLNX

Mellanox

$75.80

-1.45 (-1.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Mellanox management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

APVO

Aptevo Therapeutics

$4.33

0.01 (0.23%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aptevo Therapeutics management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

April PMI Composite Flash…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

IFRX

InflaRx

$38.78

1.67 (4.50%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
InflaRx has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

LUK

Leucadia

$24.02

-0.1 (-0.41%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leucadia management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    May

  • 04

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.